| Not Yet Recruiting | Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Canc NCT07473128 | Pharmacosmos A/S | Phase 3 |
| Recruiting | Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients NCT07242547 | Fundación GECP | Phase 2 |
| Recruiting | Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China NCT07161388 | AstraZeneca | — |
| Not Yet Recruiting | Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC NCT07200154 | Peking University Cancer Hospital & Institute | Phase 2 |
| Not Yet Recruiting | This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Combined With Chemoth NCT06978153 | Tang-Du Hospital | Phase 2 |
| Recruiting | Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomainten NCT06943235 | Fudan University | Phase 2 |
| Recruiting | BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS) NCT06773910 | SCRI Development Innovations, LLC | Phase 2 |
| Withdrawn | An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer NCT06427369 | Roswell Park Cancer Institute | Phase 1 |
| Not Yet Recruiting | A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer NCT06526624 | Hansoh BioMedical R&D Company | Phase 3 |
| Not Yet Recruiting | PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-sta NCT06375109 | Beijing Chest Hospital, Capital Medical University | Phase 2 |
| Recruiting | Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-s NCT06256237 | Shanghai Pulmonary Hospital, Shanghai, China | Phase 2 |
| Recruiting | Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) NCT06117774 | Amgen | Phase 3 |
| Suspended | MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer NCT05903092 | Hirva Mamdani | Phase 2 |
| Not Yet Recruiting | The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induct NCT05496166 | Shanghai Pulmonary Hospital, Shanghai, China | Phase 3 |
| Recruiting | Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT NCT05623267 | Sun Yat-sen University | Phase 2 / Phase 3 |
| Unknown | A Phase Ib Study of TQB2450 Combined With Anlotinib in Patients With Limited Stage Small Cell Lung Cancer Afte NCT05942508 | Jinming Yu | Phase 1 |
| Recruiting | PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer NCT04790253 | European Organisation for Research and Treatment of Cancer - EORTC | N/A |
| Recruiting | Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients NCT05443646 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Unknown | Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy NCT05483543 | Fudan University | Phase 2 |
| Active Not Recruiting | A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Rad NCT05353257 | Shanghai Henlius Biotech | Phase 3 |
| Unknown | Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer NCT05034133 | Beijing Haidian Hospital | Phase 2 |
| Completed | Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Sma NCT04952597 | BeiGene | Phase 2 |
| Recruiting | Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage NCT04829708 | Shandong Cancer Hospital and Institute | Phase 3 |
| Completed | Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease NCT02046733 | ETOP IBCSG Partners Foundation | Phase 2 |
| Completed | Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients NCT01999881 | University of Wisconsin, Madison | N/A |
| Completed | Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers NCT01935336 | University of Colorado, Denver | Phase 2 |
| Completed | Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer NCT01457469 | Wake Forest University Health Sciences | Phase 1 |
| Completed | Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer NCT00470054 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Ce NCT00084487 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tirapazamine Combined With Chemo and RT in Limited-Stage Small Cell Lung Cancer NCT00066742 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer NCT00019006 | National Cancer Institute (NCI) | Phase 1 |